TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Evaluation of BZ371B in ARDS Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old or older~* Men or Women~* In Mechanical Ventilation~* Diagnosed with Acute Respiratory Dystress Syndrome characterized by: acute beginning (less than one week from the beggining of the disease); bilateral opacity in the Torax X-Ray (not explained by stroke, atelectasis or nodules); respiratory failure not derived from cardiac failure and water overload.~* P/F lower or equal to 150 mmHg with FiO2 higher or equal to 70% and PEEP higher or or equal to 88 mmHg~* ALready executed first pronation, followed by supine position. One hour after returning from supine position.~Exclusion Criteria:~* Presence of pulmonary thromboembolism~* Presence of secondary bacterial pneumonia~* Severe Asthma~* Pregnant or lactanting women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treated Group (Type: EXPERIMENTAL): Intubated patients treated with inhaled BZ371B will receive a dose of 12 mg of BZ371B divided in two different nebulizations per day, for three cosnecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Panama and El Salvador Children's Oseltamivir Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \<10 years~* Accompanied by a parent or guardian who has the capacity to grant and sign the written informed consent and who has consented to enrollment~* Has respiratory illness as defined by modified IMCI criteria for pneumonia:~* Cough or sore throat AND Fast breathing, defined as respiratory rate 60 breaths per minutes or greater for children 0 to \<2 months, OR respiratory rate 50 breaths per minute or greater for children 2 to \<12 months, OR respiratory rate 40 breaths per minute or greater for children 12 to \<60 months, OR respiratory rate 30 breaths per minute or greater for children 5-9 years~* Planned for hospital admission~Exclusion Criteria:~* Symptom onset 7 days or more at the time of study screening where day 1 is the day of symptom onset~* Concomitant severe vomiting illness prior to enrollment that would preclude ability to take medication orally defined as more than 3 vomiting episodes in the preceding 24 hours~* Prematurity (birth at less than 37 weeks gestation) for children aged less than 3 months~* Birth weight less than 2500 grams for children aged less than 3 months~* Chronic supplemental oxygen requirement at home~* Known history of renal dysfunction~* History of gastrointestinal resection resulting in gastrointestinal abnormality that might hinder absorption of oral medication (such as short-gut syndrome)~* History of previous serious adverse reaction to oseltamivir phosphate~* Receipt of oseltamivir phosphate during the 5 days prior to presentation at the admitting hospital~* Previous enrollment in this study during a hospitalization that ended less than 14 days prior to the current admission

- Gender: ALL
- Minimum Age: None
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- Oseltamivir phosphate suspension (Type: ACTIVE_COMPARATOR): Participants assigned to the oseltamivir phosphate treatment arm will receive the appropriate weight-based dose of oseltamivir phosphate every 12 hours for 10 doses. For children 0-11 months of age, oseltamivir phosphate will be dosed as 3mg/kg/dose every 12 hours. For children 12 months and older, oseltamivir phosphate will be dosed as follows: 30 mg every 12 hours for children up to 15kg, 45mg every 12 hours for children greater than 15kg up to 23 kg, 60mg every 12 hours for children greater than 23 up to 40kg, and 75mg every 12 hours for children greater than 40kg.
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Community-dwelling children and adolescents 2 to 17 years of age.~* Written Informed Consent or Assent.~* Acute respiratory illness documented at study visit or at home with fever (oral temperature ≥ 100.0° Fahrenheit at study visit, or history of fever reported by parents, or use of antipyretic prior to study visit)~* Symptom onset less than 5 days prior to study visit.~* Subject and/or subject's legal representative is able to understand and comply with the requirements of the protocol as judged by the investigator.~Exclusion Criteria:~* Treatment with an antiviral drug for influenza (oseltamivir or Tamiflu®, zanamivir or Relenza®) during the 14 days before enrollment~* Any condition that, in the opinion of the investigator, would interfere with interpretation of subject safety or study results~* Concurrent enrollment in another clinical study~Patient already enrolled during this influenza season~* Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Q/LAIV (Type: None): FluMist Quadrivalent
- Inactivated Influenza Vaccine (Type: None): Inactivated Influenza Vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Prior to Injection and Biopsy of the Vulva

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* 18 years of age or older~* Undergoing vulva biopsy during clinic visit~* Willing and able to comply with study protocol~* Able to understand and provide informed consent~Exclusion Criteria:~* Inability to provide informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ice Pre-treatment (Type: EXPERIMENTAL): Participants will hold an exam glove filled with ice to intended biopsy area for 30 seconds prior to preparation and local anesthetic injection.
- Room Temperature Water Pre-Treatment (Type: PLACEBO_COMPARATOR): Participants will hold an exam glove filled with room temperature water to intended biopsy area for 30 seconds prior to preparation and local anesthetic injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Oral Versus Parenteral Antimicrobial Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion (must meet all of the following):~* English speaking~* The patient is hospitalized at J.W. Ruby Memorial Hospital, United Hospital Center, Berkeley Medical Center, Wheeling Hospital, or Camden Clark Medical Center~* The patient has been diagnosed with ≥1 of the following: endovascular, bone and joint, skin and soft tissue, pulmonary, gastrointestinal, or genitourinary infection~* The patient is being transitioned to 2-8 weeks of IV antibacterial therapy on hospital discharge~* The patient has capacity to participate in routine OPAT/COpAT follow-up (telephone check-ins, laboratory monitoring, and in-person or telemedicine ID Clinic follow-up)~Exclusion (may not meet any of the following):~* The patient is not appropriate for OPAT (active injection drug use, lack of infusion resources, and/or unstable outpatient environment)~* The patient is not appropriate for COpAT (unable to receive PO medication or lack of an effective PO antimicrobial option based on susceptibility testing)~* The patient is unable to give informed consent~* The patient is a prisoner, pregnant, and/or mentally handicapped~* The patient is determined unsafe for enrollment at the primary team's discretion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Experimental) (Type: EXPERIMENTAL): COpAT (oral antimicrobial therapy) on hospital discharge
- Group 2 (Control) (Type: ACTIVE_COMPARATOR): Standard of care (IV antimicrobial therapy) on hospital discharge

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Ureteric Stent Tethers on Patient Symptoms and Urinary Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age over 18 years~2. First presentation for ureteroscopy for this particular stone~3. Planned insertion of a double J-stent~4. Follow-up conducted at St. Michael's Hospital~Exclusion Criteria:~1. Age \<18years~2. Preexisting stent in place~3. Bilateral ureteric stents to be inserted~4. Patients with congenital kidney anomalies (horseshoe kidney, ectopic kidney, etc.)~5. Patients with an indwelling foley catheter~6. Patients with neurogenic bladder, chronic prostatitis, painful bladder syndrome or interstitial cystitis~7. Patients with a urinary diversion (ileal conduit, ileal neobladder)~8. Patient currently taking an α-blocker (alfuzosin, terazosin,tamsulosin, prazosin)~9. Active urinary tract infection or positive screening urine culture at preadmission~10. Pregnancy~11. Patients who will not be returning to St. Michael's Hospital for follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Double J-stent with a long tether (Type: EXPERIMENTAL): Following ureteroscopy patients will have placed a double J-stent with a long tether.
- Double J-stent without a long tether (Type: ACTIVE_COMPARATOR): Following ureteroscopy patients will have a double J-stent placed without a long tether

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed Consent Form~* Histologically confirmed metastatic RCC~* Measurable disease, as defined by RECIST~* Age ≥ 18 years~* ECOG performance status of 0 or 1~* Prior nephrectomy~* Ability and capacity to comply with study and follow-up procedures~Exclusion Criteria:~* RCC with predominantly sarcomatoid features~* Prior systemic or adjuvant therapy for RCC~* Radiotherapy for RCC within 28 days prior to Day 1~* Prior treatment with bevacizumab, sunitinib, sorafenib, axitinib, thalidomide, or other similar agents~* Current need for dialysis~* Life expectancy of \< 12 weeks~* Current, recent, or planned participation in an experimental drug study~* Inadequate organ function~* Active infection or fever \> 38.5°C within 3 days of starting treatment~* History of other malignancies within 5 years prior to Day 1~* Any other medical conditions (including mental illness or substance abuse) deemed by the clinician to be likely to interfere with a patient's ability to provide informed consent, cooperate, or participate in the study, or to interfere with the interpretation of the results~* Inadequately controlled hypertension~* Prior history of hypertensive crisis or hypertensive encephalopathy~* New York Heart Association (NYHA) Class II or greater CHF~* History of myocardial infarction or unstable angina within 6 months prior to Day 1~* History of stroke or transient ischemic attack within 6 months prior to Day 1~* Known CNS disease except for treated brain metastasis~* Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent peripheral arterial thrombosis within 6 months prior to Day 1~* History of hemoptysis (≥ 1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1~* Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)~* Major surgical procedure or anticipation of need for major surgical procedure during the course of the study~* Serious, non-healing wound; active ulcer; or untreated bone fracture~* Known hypersensitivity to any component of bevacizumab~* Pregnancy (positive pregnancy test) or lactation~* Current, ongoing treatment with full-dose warfarin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: TEST: Registry for Endoscopic Head and Neck Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients diagnosed with head and neck cancer who are candidates for definitive surgical resection of the primary tumor and who, in the opinion of the treating MDACC physician, are candidates for eHNS will be included~2. Medically fit for an endoscopic surgical resection by consensus of MDACC surgical oncology and anesthesia faculty (common best practice criteria).~3. Date of records anticipated to be reviewed would be from March 1, 2011 to June 30, 2013~4. Approximately 200 patients are expected to fit the criteria above in order to be eligible for prospective data collection and review.~Exclusion Criteria:~None.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- eHNS Participant Registry (Type: None): Participants diagnosed with head and neck cancer who are candidates for definitive surgical resection of the primary tumor and who are candidates for eHNS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Hemostatic Efficacy of Pathogen Reduced Platelets in Children Undergoing Cardiopulmonary Bypass Surgery: A Pilot Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 0 up to and including 18 years of age~* Undergoing elective cardiopulmonary bypass surgery~* Are planned to have a chest tube placed in the operating room prior to chest closure~Exclusion Criteria:~* \>/=19 years of age~* Preterm infants (less than 38-week gestational age at time of surgery)~* On extracorporeal membrane oxygenation (ECMO) or ventricular assist device prior to surgery~* Family requests limitation of blood products (i.e. Jehovah's Witness)~* Congenital bleeding disorder~* Are planned to require ECMO post-op~* Previously enrolled in the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Pathogen-reduced (PR) platelet transfusions (Type: ACTIVE_COMPARATOR): FDA approved and already used in this patient population
- Large volume delayed sampling - LVDS (Type: ACTIVE_COMPARATOR): FDA approved and already used in this patient population
- No platelet transfusion (Type: NO_INTERVENTION): Subject will not receive a platelet transfusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Optical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-3)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able and willing to undergo the test procedures, give consent, and to follow instructions.~* Signed informed consent~* Age ≥18 to 90.~* Healthy eye without prior intraocular surgery (except cataract surgery and Laser in Situ Keratomileusis) and without clinically significant vitreal, retinal or choroidal diseases, clinically significant diabetic retinopathy (subject may have diabetes), or disease of the optic nerve. Small drusen are acceptable in older subjects.~* Hispanic decent (self-reported)~* Negative history of glaucoma (not including family history)~* Intraocular pressure ≤21mmHg.~* Best corrected visual acuity ≥20/40.~* Refraction between +6 and -6 diopters and astigmatism ≤ 2 diopters.~* Axial length ≤ 26.0 mm (by optical biometry)~* Normal visual field with Glaucoma Hemifield Test and Mean Deviation within normal limits or not abnormal visual field by judgment of the ophthalmologist / optometrist~* Clinically normal appearance of the optic disc, with normal appearing neuroretinal rim with respect to color and shape. The optic disc is examined ophthalmoscopically and by evaluation of stereo photographs.~* If both eyes are eligible, both eyes enter the study.~Exclusion Criteria:~* Vulnerable subjects (as defined in ISO 14155 GCP) with the exception of employees of the site, and, if applicable, students of the respective university. Staff that is listed on the delegation form are excluded from participation.~* Subjects unable to read or write~* Unreliable visual field. The reliability indices should be used as guide as well as the perimetrist's notes.~* Unusable disc stereo photos.~* Inability to undergo the tests.~* Insufficient quality of Spectralis OCT images (this is not determined until after Spectralis OCT examination, and is an unusual circumstance).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Normal healthy volunteers (Type: EXPERIMENTAL): imaging with Heidelberg Spectralis OCT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PHIL Evaluation in the Endovascular Treatment of Intracranial Cerebral ArterioVenous Malformation (cAVM)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. All patients with a ruptured or unruptured and previously endovascularly untreated cAVM that are eligible for endovascular treatment with PHIL® alone or in conjunction with N-Butyl cyanoacrylate glue (NBCA) and/or coils (e.g. if pressure cooking technique is needed or used).~2. All patients with a previously endovascularly treated cAVM in which NBCA and/or coils (but not another non-adhesive liquid embolic agent) have been used may be included.\*\*~3. All patients with a remaining cAVM, ruptured or unruptured, that has previously been treated with NS and/or RT may be included.~4. Patient or patient's legally authorized representative has received information about data collection and has signed and dated an Informed Consent Form. (Based on the country's regulation).~Exclusion Criteria:~1. cAVM not eligible for endovascular treatment~2. cAVM previously treated with a non-adhesive liquid embolic agent other than PHIL®~3. Treatment requiring the use of any other non-adhesive embolic liquid~4. Patient is allergic to iodine~5. Premature and newborn infant~6. Patient with renal failure or significant liver impairment~7. Patient is participating in another study evaluating other medical devices, other procedures or medications.~8. Any other condition that might prevent patient participation in the study or follow up~9. Patient does not want to and/or refuses to give consent to the collection and processing of data required for centralized monitoring

- Gender: ALL
- Minimum Age: 28 Days
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of NPL-2003 in Adolescents With Obsessive Compulsive Disorder (OCD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Meets DSM-IV criteria for Obsessive Compulsive Disorder.~* CY-BOCS score of greater or equal to 16 at screening.~* NIMH Global OC Scale score of 7 or higher at screening.~Exclusion Criteria:~* Patients planning to commence cognitive behaviour therapy during the period of the study or those who have begun cognitive behaviour therapy within 8 weeks prior to enrolment.~* Autistic Disorder or Pervasive Developmental Disorder.~* Moderate or severe mental retardation.~* Severe renal insufficiency.~Other protocol-defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues